Inquiry into some gap among oseltamivir use and severe abnormal behavior in Japanese children and adolescents with influenza
| Autor: | Chiaki Miyazaki, Kiyosu Taniguchi, Yasushi Ohkusa, Tamie Sugawara, Nobuhiko Okabe, Mariko Y. Momoi |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Male Oseltamivir Pediatrics medicine.medical_specialty Adolescent 030106 microbiology Acids Carbocyclic Behavioral Symptoms Cyclopentanes Guanidines Severity of Illness Index Cohort Studies 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Zanamivir Influenza Human medicine Humans Pharmacology (medical) 030212 general & internal medicine General Pharmacology Toxicology and Pharmaceutics Child biology business.industry Incidence General Medicine Laninamivir chemistry Research Design Relative risk biology.protein Peramivir Abnormality business Neuraminidase medicine.drug Cohort study |
| Zdroj: | Drug discoveriestherapeutics. 12(6) |
| ISSN: | 1881-7831 |
| Popis: | The Fukushima research has examined data form a cohort study of 10,000 Japanese children under 18 years old with influenza during three months to demonstrate that the relative risk of A-type abnormal behavior of patients with oseltamivir was 30 times greater than without oseltamivir. By contrast, our research group found that patients who had been administered no neuraminidase inhibitors (NI) or those administered peramivir had higher risk of abnormal behavior than those administered oseltamivir, zanamivir, or laninamivir. A plausible explanation for this gap is that the two studies specifically examined different criteria to report abnormal behavior. In actually, some A-type abnormal behavior might not be life-threatening. Our definition of severe abnormal behavior is better matched to public health concerns and comparison among incidents according to the administered drug is more appropriate as an analytical procedure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|